Modality
Cell Therapy
MOA
BCL-2i
Target
Menin
Pathway
Fibrosis
NASH
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
Aug 2019
→ Dec 2029
Phase 1Current
NCT06620401
2,133 pts·NASH
2019-12→2029-12·Terminated
NCT08738704
2,559 pts·NASH
2019-08→2029-11·Recruiting
4,692 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-103.6y awayPh2 Data· NASH
2029-12-163.7y awayPh2 Data· NASH
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Recruit…
P1/2
Termina…
Catalysts
Ph2 Data
2029-11-10 · 3.6y away
NASH
Ph2 Data
2029-12-16 · 3.7y away
NASH
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06620401 | Phase 1/2 | NASH | Terminated | 2133 | SRI-4 |
| NCT08738704 | Phase 1/2 | NASH | Recruiting | 2559 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |